Core Viewpoint - The company has successfully implemented a systematic investment strategy through regular fund contributions, demonstrating the potential for profitability in fund investments despite market fluctuations [4][6][13]. Group 1: Investment Strategy - The company began its systematic investment in funds on June 15, 2023, during a market downturn, initially investing in two funds: a pharmaceutical industry fund and a CSI 300 index fund [4]. - Despite facing losses initially, the company maintained its investment strategy, increasing contributions during market dips, which ultimately led to positive returns [4][6]. - By May 23, 2024, the CSI 300 index fund achieved an 8% holding return, translating to an annualized return of over 10% [4]. Group 2: Performance and Adjustments - The company executed multiple rounds of profit-taking, with the first occurring after achieving an 8% return on the CSI 300 index fund [4][6]. - Subsequent investments included the S&P 500 index fund and a gold index fund, with profit-taking occurring after achieving approximately 10% returns on these investments [8][9]. - As of June 5, 2025, the company had executed five rounds of profit-taking across various funds, indicating a proactive approach to managing investment positions [9][11][13]. Group 3: Overall Results - The overall performance of the funds has been positive, with all funds sold at a profit after multiple rounds of profit-taking [13]. - The company also implemented a savings plan, investing in a bond fund that yielded a 3.61% return, showcasing diversification in investment strategies [13][16]. - The conclusion drawn from the company's experience is that fund investments can be profitable when approached with a disciplined strategy, countering the notion that fund investments do not yield returns [16].